Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canadian National Railway Co. (CNI) vs Davita Inc (DVA) Price & Performance

Canadian National Railway Co.Trade
Davita IncTrade

Price performance (Past 24H)

Key statistics

Canadian National Railway Co. vs Davita Inc — how do they compare? Canadian National Railway Co. trades at $126.3 (market cap $76.28B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Canadian National Railway Co. is far larger — about 6.7× Davita Inc's market cap, and Canadian National Railway Co. pays a 2.06% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

CNIDVA
Market Cap
$76.28B$11.38B
Sector
IndustrialsHealth
52-Week High
$130.58$240.96
52-Week Low
$90.91$103.87
Enterprise Value
$92.31B$24.10B
Dividend Yield
2.06%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canadian National Railway Co.

Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.

Read more on CNI

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA